140 reports of this reaction
1.5% of all EDOXABAN TOSYLATE reports
#19 most reported adverse reaction
HAEMATURIA is the #19 most commonly reported adverse reaction for EDOXABAN TOSYLATE, manufactured by Daiichi Sankyo Inc.. There are 140 FDA adverse event reports linking EDOXABAN TOSYLATE to HAEMATURIA. This represents approximately 1.5% of all 9,635 adverse event reports for this drug.
Patients taking EDOXABAN TOSYLATE who experience haematuria should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMATURIA is a less commonly reported adverse event for EDOXABAN TOSYLATE, but still significant enough to appear in the safety profile.
In addition to haematuria, the following adverse reactions have been reported for EDOXABAN TOSYLATE:
The following drugs have also been linked to haematuria in FDA adverse event reports:
HAEMATURIA has been reported as an adverse event in 140 FDA reports for EDOXABAN TOSYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMATURIA accounts for approximately 1.5% of all adverse event reports for EDOXABAN TOSYLATE, making it a notable side effect.
If you experience haematuria while taking EDOXABAN TOSYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.